Progress in cancer chemoprevention

Annals of the New York Academy of Sciences

Volumn 889, Issue , 1999, Pages 1-13

  Kelloff, Gary J ^a   Crowell, James A ^a   Steele, Vernon E ^a   Lubet, Ronald A ^a   Boone, Charles W ^a   Malone, Winfred A ^a   Hawk, Ernest T ^a   Lieberman, Ronald ^a   Lawrence, Julia A ^a   Kopelovich, Levy ^a   Ali, Iqbal ^a   Viner, Jaye L ^a   Sigman, Caroline C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ALITRETINOIN; ALPHA TOCOPHEROL; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CALCIUM; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EFLORNITHINE; FENRETINIDE; GENISTEIN; IBUPROFEN; ISOFLAVONE DERIVATIVE; ISOTRETINOIN; LYCOPENE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; PHENETHYL ISOTHIOCYANATE; POLYPHENOL; RETINOID; SELENIUM; SULINDAC; TAMOXIFEN; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CARCINOGENESIS; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOXICITY; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; KNOCKOUT GENE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; RISK ASSESSMENT; TEA; TRANSGENIC MOUSE;

ANIMALIA; CAMELLIA SINENSIS; MUS MUSCULUS;

EID: 0033403560     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb08718.x     Document Type: Conference Paper

References (38)

1. 1. Kelloff, G.J. et al. 1997. Progress in clinical chemoprevention. Semin. Oncol. 24: 241-252.
2. 2. Hong, W.K. & M.B. Sporn. 1997. Recent advances in chemoprevention of cancer. Science 278: 1073-1077.
3. 3. Kelloff, G.J. et al. 1996. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology 10: 1471-1484.
4. 4. Kelloff, G.J. et al. 1994. Mechanistic considerations in chemopreventive drug development. J. Cell. Biochem. Suppl. 20: 1-24.
5. 5. Kelloff, G.J. et al. 1996. Mechanistic considerations in the evaluation of chemopreventive data. Principles of Chemoprevention, IARC Scientific Publication No. 139, Lyon, France: International Agency for Research on Cancer. 203-221.
6. 6. Kelloff, G.J. et al. 1997. Risk biomarkers and current strategies for cancer chemoprevention. J. Cell. Biochem. Suppl. 25: 1-14, 1996.
7. 7. Bagheri, D. et al. 1989. Database of inhibitors of carcinogenesis. J. Environ. Sci. Health 6: 261-414.
8. 8. Steele, V.E. et al. 1996. Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. J. Cell. Biochem. Suppl. 26: 29-53.
9. 9. Steele, V.E. et al. 1994. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI chemoprevention testing program. J. Cell. Biochem. Suppl. 20: 32-54.
10. 10. Fisher, B. et al. 1998. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P1 Study. J. Natl. Cancer Inst. 90: 1371-1388.
11. 11. De Palo, G. et al. 1996. Ongoing clinical chemoprevention study of breast cancer with fenretinide. Int. Congr. Ser. 1120: 249-254.
12. 12. Hong, W.K. et al. 1990. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323: 795-801.
13. 13. Heinonen, O.P. et al. 1998. Prostate cancer and supplementation with α-tocopherol and β-carotene: Incidence and mortality in a controlled trial. J. Natl. Cancer Inst. 90: 440-446.
14. 14. Clark, L. C. et al. 1998. Decreased incidence of prostate cancer with selenium supplementation: Results of a doubleblind cancer prevention trial. Br. J. Urol. 81: 730-734.
15. 15. Baron, J.A. et al. 1999. Calcium supplements for the prevention of colorectal adenomas. Calcium polyp prevention study group. N. Engl. J. Med. 340: 101-107.
16. 16. Kensler, T.W. et al. 1998. Oltipraz chemoprevention trial in Qidong, People's Republic of China: Modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev. 7: 127-134.
17. 17. Kelloff, G.J., et al. 1999. Chemoprevention of prostate cancer: Concepts and strategies. Eur. J. Urol. 35: 342-350.
18. 18. Kelloff, G.J. et al. 1996. Clinical development plan: Tea extracts, green tea polyphenols, epigallocatechin gallate. J. Cell. Biochem. Suppl. 26: 236-257.
19. 19. Giovannucci, E.G. et al. 1995. Intake of carotenoids and retinol in relation to risk of prostate cancer. J. Natl, Cancer Inst. 87:1767-1776.
20. 20. Kelloff, G.J. et al. 1996. Clinical development plan: Genistein. J. Cell. Biochem. Suppl. 26: 114-126.
21. 21. Kelloff, G.J. et al. 1996. Clinical development plan: Curcumin. J. Cell. Biochem. Suppl. 26: 72-85.
22. 22. Kelloff, G.J, et al. 1996. Clinical development plan: Phenethyl isothiocyanate (PEITC). J. Cell. Biochem. Suppl. 26: 149-157.
23. 23. Kelloff, G.J. et al. 1996. Clinical development plan: Indole-3-carbinol. J. Cell. Biochem. Suppl. 26: 127-136.
24. 24. Kelloff, G.J. et al. 1996. Clinical development plan: Perillyl alcohol. J. Cell. Biochem. Supp. 26: 137-148.
25. 25. Kelloff, G.J. et al. 1995. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol. Biomarkers Prev. 4: 1-10.
26. 26. Kelloff, G.J. et al. 1994. Surrogate endpoint biomarkers for Phase II cancer chemoprevention trials. J. Cell. Biochem. Suppl. 19: 1-9.
27. 27. Lawrence, J.A. et al. 1999. The clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women. J. Cell. Biochem. Suppl. In press.
28. 28. Kelloff, G.J. et al. 1998. Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev. 7: 65-78.
29. 29. Hamilton, S.R. 1992. The adenoma-adenocarcinoma sequence in the large bowel: Variations on a theme. J. Cell. Biochem. 16 (Suppl. G): 41-46.
30. 30. Lipkin, M. 1992. Prototypic applications of intermediate endpoints in chemoprevention. J. Cell. Biochem. 16 (Suppl. G): 1-13.
31. 31. Winawer, S.J. et al. 1990. Risk and surveillance of individuals with colorectal polyps. Bull. W.H.O. 68: 789-795.
32. 32. Kawamori, T. et al. 1998. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58: 409-412.
33. 33. Singh, G. et al. 1994. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharm. Ther. 62: 175-191.
34. 34. Mitchell, J.A. et al. 1993. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90: 11693-11697.
35. 35. Oshima, M. et al. 1996. Suppression of intestinal polyposis in Ape delta 716 knock-out mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803-809.
36. 36. Kelloff, G.J. et al. 1994. Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials. Cancer Res. 54: 2015s-2024s.
37. 37. Wattenberg, L.W. et al. 1997. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res. 57: 5489-5492.
38. 38. Fahey, J.W., Y.-S. Zhang & P. Talalay. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc. Natl. Acad. Sci. USA 94: 10367-10372.